Search
Research
The airway epithelium is a direct source of matrix degrading enzymes in bronchiolitis obliterans syndromeLong-term survival after lung transplantation is hindered by the development of bronchiolitis obliterans syndrome (BOS).
Research
Bronchial brushings for investigating airway inflammation and remodellingAsthma is the commonest medical cause for hospital admission for children in Australia, affects more than 300 million people worldwide, and is incurable...
Research
Cyanide in bronchoalveolar lavage is not diagnostic for Pseudomonas aeruginosa in children with cystic fibrosisEarly detection of the cyanobacterium Pseudomonas aeruginosa in the lungs of young children with cystic fibrosis (CF) is considered the key to delaying...
Research
Randomised controlled trials in cystic fibrosis: What, when and how?The major morbidity and mortality from cystic fibrosis (CF) comes from progressive lung disease with bronchiectasis leading to respiratory failure
Research
Decreased fibronectin production significantly contributes to dysregulated repair of asthmatic epitheliumIn human asthma, and experimental allergic airways disease in mice, antigen-presenting cells and CD4(+) effector cells at the airway mucosa orchestrate, and CD4
Research
Successful establishment of primary small airway cell cultures in human lung transplantationThe study of small airway diseases such as post-transplant bronchiolitis obliterans syndrome (BOS) is hampered by the difficulty in assessing peripheral airway
The Advancing Innovation in Respiratory (AIR) Health Team is a multi-disciplinary group with skills in clinical medicine, physiology, psychology, and in cellular and molecular biology, that are committed to improving the lives of children with respiratory diseases and their families.
Research
Cystic Fibrosis Early Surveillance ProgramResearchers are able to track the progress of lung disease through a comprehensive longitudinal set of biological samples, images and data archives.
Research
COMBAT CF: A phase 3 multi-centre randomized placebo-controlled study of azithromycin in the primary prevention of radiologically-defined bronchiectasis in infants with cystic fibrosis.A phase 3 multi-centre randomized placebo-controlled study of azithromycin in the primary prevention of radiologically-defined bronchiectasis in infants with cystic fibrosis